Johnson & Johnson to Acquire Momenta Pharmaceuticals, Inc., Expanding Janssen ’s Leadership in Novel Treatments for Autoimmune Diseases
NEW BRUNSWICK, N.J., August 19, 2020 – Johnson & Johnson (NYSE:JNJ) today announced it has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. (Momenta), a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash transaction for approximately $6.5 billion. This acquisition provides an opportunity for the Janssen Pharmaceutical Companies of Johnson & Johnson to broaden its leadership in immune-mediated diseases and drive further growth through expansion into autoantibody-driven disease. The transaction will include full global rights to nipocalimab (M281), a clinically validated, potentially best-in-class anti-FcRn antibody. Nipocalimab gives Janssen the opportunity to reach significantly more patients by pursuing indications across many autoimmune diseases with substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Nipocalimab recently received a rare pediatric disease designation from the U.S. Food and Drug Administration. Momenta’s expertise in FcRn mechanisms is especially important for nipocalimab as it supports and accelerates the development of a medicine designed to target a number of autoantibody-driven conditions across several of Janssen’s established therapeutic areas. Janssen expects nipocalimab to contribute to its goals of achieving above-market growth over the mid and long term. Autoimmune disease...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news
More News: Allergy & Immunology | Anemia | Autoimmune Disease | Biology | Brain | Cancer & Oncology | Cardiology | Cardiovascular | Coronavirus | COVID-19 | Dermatology | Environmental Health | Food and Drug Administration (FDA) | Genetics | Government | Health Management | Heart | Hematology | Hypertension | Infectious Diseases | International Medicine & Public Health | Learning | Legislation | Mergers and Aquisitions | Molecular Biology | Myasthenia Gravis | Neurology | Neuroscience | Outbreaks | Pandemics | Pediatrics | Pharmaceuticals | Pulmonary Hypertension | Rare Diseases | Rheumatology | Science | Skin | Universities & Medical Training | Vaccines | Websites